Prevention of cisplatin-induced delayed emesis: still unsatisfactory

被引：0

作者：

Ruggeri, B

Ballatori, E

Roila, F ^{[1
]}

De Angelis, V

Tonato, M

Del Favero, A

Ciccarese, G

Basurto, C

Ciccarese, G

Palladino, MA

Porrozzi, S

Picciafuoco, M

Contu, SA

Olmeo, N

Pazzola, A

Pilo, L

Tateo, PS

Salamano, S

Morana, S

Lucchino, S

Ricci, S

Antonuzzo, A

Allegrini, G

Galli, L

Conte, PF

Massidda, B

Ionta, MT

Scanu, A

Murru, R

Picece, V

Nicodemo, M

Recaldin, E

Nuzzo, A

Laudadio, L

D'Ostilio, N

Locatelli, MC

D'Antona, A

Luporini, G

Scagliotti, G

Selvaggi, G

Mattei, A

Favalli, G

Gambino, A

Fava, S

Grimi, E

Fava, S

Grimi, E

Scarfone, G

Bolis, MC

Alessandroni, P

机构：

[1] Policlin Hosp, Div Med Oncol, I-06122 Perugia, Italy

[2] Univ Aquila, Dept Internal Med & Publ Hlth, Med Stat Unit, I-67100 Laquila, Italy

[3] Univ Perugia, Dept Internal Med & Oncol Sci, I-06100 Perugia, Italy

来源：

SUPPORTIVE CARE IN CANCER | 2000年 / 8卷 / 03期

关键词：

delayed emesis; cisplatin; antiemetics;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The incidence of and prognostic factors in cisplatin-induced delayed emesis were evaluated in 522 naive cancer patients. They each received an intravenous combination of ondansetron and one of four different doses of dexamethasone for the prevention of acute emesis and a combination of orally administered metoclopramide plus intramuscular dexamethasone for the prevention of delayed emesis. Despite the best prophylaxis for acute and delayed emesis, 37.4% / 57.1% of patients experienced delayed vomiting / nausea. The presence of acute vomiting / nausea was the main prognostic factor in delayed vomiting / nausea; therefore, a multifactorial analysis of the results achieved during the delayed phase adjusted for those obtained during the acute phase should be carried out in every study evaluating the efficacy of different antiemetic drugs for delayed emesis.

引用

页码：229 / 232

页数：4

共 50 条

[11] ONDANSETRON FOR CISPLATIN-INDUCED EMESIS
ATHANASSIADES, PH
MATSOUKI, K
GIANNIOTI, H
JOURNAL OF CHEMOTHERAPY, 1993, 5 : 749 - 749
[12] EFFICACY OF REPEATED COURSES OF ONDANSETRON IN THE PREVENTION OF CISPLATIN-INDUCED EMESIS
MARTY, M
RICHARD, A
DALLENS, H
BULLETIN DU CANCER, 1993, 80 (07) : 618 - 623
[13] Efficacy of droperidol in the prevention of cisplatin-induced delayed emesis: a double-blind, randomised parallel study
Minegishi, Y
Ohmatsu, H
Miyamoto, T
Niho, S
Goto, K
Kubota, K
Kakinuma, R
Kudoh, S
Nishiwaki, Y
EUROPEAN JOURNAL OF CANCER, 2004, 40 (08) : 1188 - 1192
[14] Antiemetic effect of dexamethasone on cisplatin-induced early and delayed emesis in the pigeon
Tanihata, S
Oda, S
Nakai, S
Uchiyama, T
EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 484 (2-3) : 311 - 321
[15] Action of glucocorticoids to antagonise cisplatin-induced acute and delayed emesis in the ferret
Sam, TSW
Chan, SW
Rudd, JA
Yeung, JHK
EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 417 (03) : 231 - 237
[16] An open label study of tropisetron for acute and delayed cisplatin-induced emesis
Olver, IN
EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1224 - 1224
[17] HIGH-DOSES OF METOCLOPRAMIDE OR DROPERIDOL IN THE PREVENTION OF CISPLATIN-INDUCED EMESIS
SALLER, R
HELLENBRECHT, D
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1986, 22 (10): : 1199 - 1203
[18] Prevention of cisplatin-induced emesis by a neurokinin-1-receptor antagonist
Roila, F
Ballatori, E
Del Favero, A
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (24): : 1926 - 1927
[19] Prevention of apomorphine or cisplatin-induced emesis in the dog by a combination of methylnaltrexone and morphine
Foss, JF
Yuan, CS
Roizen, MF
Goldberg, LI
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 42 (04) : 287 - 291
[20] Action of metyrapone and tetracosactrin to modify cisplatin-induced acute and delayed emesis in the ferret
Sam, TSW
Kan, KKW
Ngan, MP
Rudd, JA
Yeung, JHK
EUROPEAN JOURNAL OF PHARMACOLOGY, 2003, 466 (1-2) : 163 - 168

← 1 2 3 4 5 →